Yangzhou, China, Dec. 05, 2025 — Meihua International Medical Technologies Co., Ltd. (Nasdaq: MHUA), a China-based manufacturer of Class I, II, and III disposable medical devices, announced it received a delisting notification from Nasdaq on December 2, 2025. Nasdaq’s staff determined to delist Meihua’s shares because the company failed to meet Nasdaq Listing Rule 5550(a)(2).
The company had previously been notified on December 3, 2024, that its shares were trading below $1 for 30 consecutive business days, putting it in non-compliance with Listing Rule 5450(a)(1). Meihua was given until June 2, 2025, to regain compliance. After transferring to The Nasdaq Capital Market on June 6, 2025, the compliance period was extended to December 1, 2025.
Although Meihua implemented a 1:16 reverse share split on November 24, 2025, it did not maintain a minimum bid price of $1.00 for at least 10 consecutive business days before the December 1, 2025 deadline. Trading of Meihua’s shares will be suspended on December 9, 2025.
Meihua had until December 9, 2025, to appeal the delisting decision and submitted a hearing request on December 4, 2025.
Furthermore, on December 1, 2025, Nasdaq informed Meihua that it also failed to comply with Listing Rule 5550(a)(4), which requires listed companies to have a minimum of 500,000 publicly held shares. As of December 1, 2025, Meihua’s publicly held shares were below this threshold, providing an additional reason for delisting.
About Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies Co., Ltd. is a manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under the Company’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.
For more information, please visit .
Follow us on Webull: .
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact in this press release are forward-looking statements, including but not limited to, the use of proceeds from the Company’s offering, the intent, belief or current expectations of Top KingWin and members of its management, as well as the assumptions on which such statements are based. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For further information, please contact.
IR Department
Email:
Tel: +86-0514-89800199
“`